The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Tumor Motion Management in Radiotherapy Using 4D-MRI
- Conditions
- Cancer
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2015-10-12
- Target Recruit Count
- 32
- Registration Number
- NCT01934855
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
- Conditions
- Non-Small Cell Lung CancerEpigenetic Therapy
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2024-05-03
- Target Recruit Count
- 143
- Registration Number
- NCT01928576
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸UPMC Cancer Center- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: Brentuximab vedotinBiological: Rituximab
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2018-10-17
- Target Recruit Count
- 6
- Registration Number
- NCT01900496
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Canceer Center, Baltimore, Maryland, United States
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2020-05-19
- Target Recruit Count
- 83
- Registration Number
- NCT01896869
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
- Conditions
- Previously Treated Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2020-10-06
- Target Recruit Count
- 118
- Registration Number
- NCT01896856
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma
- Conditions
- Metastatic Osteosarcoma
- Interventions
- Drug: Sm-EDTMPOther: Autologous Stem Cell InfusionRadiation: External Beam Radiotherapy
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2019-10-29
- Target Recruit Count
- 4
- Registration Number
- NCT01886105
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
- Conditions
- MSI Positive Colorectal CancerMSI Negative Colorectal CancerMSI Positive Non-Colorectal Cancers
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2020-02-06
- Target Recruit Count
- 113
- Registration Number
- NCT01876511
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Stanford University, Stanford, California, United States
POWER-remote Weight Loss Program in Early Stage Breast Cancer
- Conditions
- Early Stage Breast Cancer
- Interventions
- Behavioral: POWER-remoteBehavioral: Self-directed
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2018-02-05
- Target Recruit Count
- 96
- Registration Number
- NCT01871116
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
- Conditions
- Myeloma
- Interventions
- Drug: Lenalidomide, Dexamethasone, and MEDI-551
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2018-09-10
- Target Recruit Count
- 20
- Registration Number
- NCT01861340
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2020-06-29
- Target Recruit Count
- 102
- Registration Number
- NCT01858558
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States